Figure 3. Effects of MMP inhibitor (MMPi), indomethacin (Indo), or their vehicle (V) treatments on PAR₂ agonist peptide (SLIGRL)-induced alveolar bone loss (A) and granulocyte infiltration (B), at 7 days after the beginning of PAR₂ agonist treatment. *Significant difference (P < 0.05) compared with the V + SLIGRL group at the same time period (ANOVA). N = 8 animals/group/period; data expressed as means ± SEM.